Citius Pharma Reports $5.6 Million Net Revenue in H1 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: May 15 2026

0mins

CTXR+1.11%

CTOR+1.36%

Explore Agentic TradingLet AI Trade for You

Source: PRnewswire

Strong Financial Performance: Citius Pharma reported $5.6 million in net revenue for the first half of fiscal 2026, achieving approximately 80% gross margins, indicating strong market acceptance and sales potential for LYMPHIR®, which is expected to drive future growth.
Financing to Support Growth: Citius Oncology secured up to $36.5 million in combined debt and equity financing through a senior secured credit facility and the exercise of outstanding warrants, alongside Citius Pharma's $5 million registered direct offering, which is anticipated to fund market expansion and commercial efforts for LYMPHIR.
Enhanced Patient Coverage: Currently, Citius Oncology's LYMPHIR has achieved nearly 100% payer coverage among commercial lives, with 83% of target accounts included on formularies or under review, significantly enhancing market penetration and sales opportunities for the product.
Positive Clinical Data: Citius Pharma has also received encouraging preliminary data from two investigator-initiated studies, demonstrating LYMPHIR's potential as a platform asset in combination therapies, further strengthening the company's competitive position in the oncology treatment market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CTXR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CTXR

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Citius Oncology's LYMPHIR Shows Promising Phase 1 Clinical Data

Jun 01 2026PRnewswire

Significant Clinical Efficacy: At the 2026 ASCO Annual Meeting, Citius Oncology presented data showing that 48% of patients (10 out of 21) achieved clinical benefit with a median progression-free survival of 20.5 months when treated with LYMPHIR in combination with pembrolizumab, indicating strong efficacy in heavily pre-treated patients.
Manageable Safety Profile: The safety characteristics observed in the study were manageable in heavily pre-treated patients, particularly for those who progressed after immunotherapy, providing a potential therapeutic option to address the unmet needs in this patient population.
Future Research Plans: Citius Oncology is planning a Phase 2 expansion study to further evaluate the combination of LYMPHIR and pembrolizumab in a broader population of gynecologic cancer patients, especially those previously exposed to immunotherapy, demonstrating the company's ongoing commitment to this area.
Substantial Market Potential: The initial market for LYMPHIR in the U.S. is estimated to exceed $400 million, and as treatment demands grow, Citius Oncology's robust intellectual property protections will further enhance its competitive positioning and support future commercialization efforts.

Citius Pharmaceuticals Rated Highly by Wall Street Analysts

May 24 2026Yahoo Finance

Analyst Rating: On May 18, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and a $4 price target, indicating an upside potential of 843.40%, reflecting strong market optimism about the company's future performance.
Therapy Approval: Citius's lead therapy, LYMPHIR, has received approval for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma, marking a significant advancement in the oncology sector and expected to drive market share growth.
Commercialization Progress: H.C. Wainwright noted that early commercial launch metrics for LYMPHIR are encouraging, with nearly full commercial insurance coverage and strong formulary positioning across target healthcare accounts, indicating the company's proactive efforts in expanding market access.
International Shipment: Citius Oncology announced on April 29 the first shipment of LYMPHIR into Europe through a regional distribution partner, which management views as a strategic milestone in expanding international access for patients with limited treatment options.

Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026

May 19 2026NASDAQ.COM

Deteriorating Financials: Citius Pharmaceuticals reported a net loss of $21.23 million for Q2 FY 2026, translating to a loss of $0.95 per share, nearly doubling from the $10.92 million loss in the same quarter last year, primarily due to $26.39 million in general and administrative expenses, including a one-time $19.7 million charge for contract research organization cancellation.
Sales Growth: The company achieved $5.6 million in sales for LYMPHIR in Q2, with 83% of target accounts added, although revenue declined compared to initial orders in Q1, indicating early market acceptance and potential for future growth.
Research Advancements: Citius is conducting multiple clinical trials for LYMPHIR, including a Phase 1 trial for gynecological cancers and another assessing LYMPHIR prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma patients, with positive safety topline results suggesting market expansion opportunities.
Cash Flow Concerns: As of March 31, 2026, the company held $4.6 million in cash and cash equivalents, expected to fund operations until November 2026, reflecting financial strain amid ongoing losses that could impact future R&D and marketing efforts.

Citius Pharmaceuticals Reports Q2 2026 Financial Results

May 15 2026seekingalpha

Financial Highlights: Citius Pharmaceuticals reported a Q2 2026 GAAP EPS of -$0.95, indicating ongoing challenges in profitability, although product revenues reached $1.7 million, a notable improvement from zero revenue in Q2 2025.
Revenue Growth: The $1.7 million in net product revenue for Q1 2026 marks an initial success in revenue generation, though it remains insufficient compared to industry standards, highlighting potential market acceptance.
Expense Analysis: R&D expenses totaled $1.6 million, significantly down from $3.8 million in Q1 2025, suggesting a more cautious approach to R&D spending aimed at optimizing resource allocation.
Surge in Administrative Costs: Administrative expenses soared to $26.4 million in Q1 2026, up from $4.8 million in Q1 2025, reflecting increased operational and management spending pressures that could impact future financial stability.

Citius Oncology Reports Q2 2026 Financial Results and Business Update

May 15 2026PRnewswire

Revenue Growth: Citius Oncology reported $5.6 million in net revenue for the first half of fiscal 2026, reflecting only four months of sales since LYMPHIR's launch, indicating a gradual increase in market acceptance and potential for future revenue growth.
Successful Financing: The company secured up to $36.5 million in debt and equity capital after the quarter-end, providing essential funding for the buildout of its commercial team, with full deployment expected by mid-summer.
Market Coverage Expansion: Currently, 83% of target accounts have added LYMPHIR to their formularies or are under review, with nearly 100% payer coverage and no reimbursement denials, demonstrating increasing acceptance and demand for the product in the market.
Reduced R&D Expenses: R&D expenses for Q2 2026 were $1.1 million, significantly down from $3.1 million in the same period last year, reflecting a decrease in clinical development activities, which helps improve the company's financial position.